Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

It seems counterintuitive, if not implausible, that a company which has revolutionised Western health and promises to ...

Investing.com - Novo Nordisk (NYSE:NVO)’s weight-loss and diabetes drugs Wegovy and Ozempic could face increased pressure in the future, weighing on the Danish pharmaceutical group’s earnings, ...

Paul Curran, MPharm, a clinical pharmacist with Optimal You in the UK, says there is one nasty side effect, in particular, ...

Novo Nordisk announces a leadership transition as Lars Fruergaard Jørgensen welcomes new CEO Doug Doustdar. Doustdar aims to ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Ozempic may be adding some spring to your step — but it might also be taking a bite out of your smile. As the popularity of weight-loss drugs surges, a new concern is emerging: “Ozempic teeth.” ...